Coya Therapeutics, Inc. (COYA): Shareholders' Equity
$43.03M
As of 2025-12-31
$43.28M
As of 2026-06-30
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $43.03M | +8.7% | 2026-03-16, Balance as of period end |
| 2024-12-31 | $39.58M | +11.1% | 2026-03-16, Balance as of period end |
| 2023-12-31 | $35.64M | n/m | 2025-03-18, Balance as of period end |
| 2022-12-31 | -$8.39M | n/m | 2024-03-19, Balance as of period end |
| 2021-12-31 | $3.64M | n/a | 2023-03-29, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $43.03M | +8.7% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $103.08M | -33.7% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $26.50M | -53.7% |
| Adagene Inc. (ADAG) | 2025-12-31 | $35.35M | -30.0% |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $4.53B | -3.4% |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $581.76M | -22.9% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $130.66M | +91.5% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $136.31M | +159.7% |
| BioAge Labs, Inc. (BIOA) | 2025-12-31 | $272.05M | -15.8% |
Compare COYA, ACRS, BOLT, ADAG side by side · Screen every company in Pharmaceutical Preparations ↗